Molecular mechanisms of cephalosporins resistance in gramnegative bacteria of the enterobacteriaceae family

Antibiotiki i Khimioterapiya

Volumn 49, Issue 3, 2004, Pages 6-16

  Sidorenko, S V ^a   Berezin, A G ^a   Ivanov, D V ^a  

^a National Research Centre of Antibiotics   (Russian Federation)

Author keywords

Beta lactamases; Enterobacteriaceae; Resistance

Indexed keywords

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; PROTEUS MIRABILIS;

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; ENTEROBACTERIACEAE; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; RUSSIAN FEDERATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORIN RESISTANCE; ENTEROBACTERIACEAE; HUMANS; POLYMERASE CHAIN REACTION; RUSSIA;

EID: 6344228221     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Winokur P. L., Canton R., Casellas J. M., Legakis N. Variations in prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific Region. Clin Infect Dis 2001; 32: S94-S104.
2. Jones R. N., Pfaller M. A. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum β-lactamase in Europe. Clinl Microbiol Infect 2003; 9: 708-712.
3. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bactera that grow aerobically; Approved standard / Sixth Ed. National Committee for Clinical Laboratory Standards, Wayne, 2003.
4. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. /Thirteenth inform suppl. Approved standard M100-S13. National Committee for Clinical Laboratory Standards, Wayne, 2003.
5. Livermore D. M. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
6. Paterson D. L., Ko W. C., Gottberg A. V. et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.
7. Edelstein M., Pimkin M., Palagin I. et al. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003; 47: 3724-3732.
8. Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Ibid; 2004; 48: 1-14.
9. Bonnet R., Sampaio J. L., Chanal C. et al. A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Ibid; 2000; 44: 3061-3068.
10. Petroni A., Corso A., Melano R. et al. Plasmidic extended-spectrum β- lactamases in Vibrio cholerae O1 El Tor isolates in Argentina. Ibid; 2002; 46: 1462-1468.
11. Radice M., Power P., Di Conza J., Gutkind G. Early dissemination of CTX-M-derived enzymes in South America. Ibid; 602-604.
12. Quinteros M., Radice M., Gardella N. et al. Extended-spectrum β-lactamases in Enterobacteriaceae in Buenos Aires, Argentina, public hospitals. Ibid; 2003; 47: 2864-2867.
13. Li C. R., Li Y., Zhang P. A. Dissemination and spread of CTX-M extended-spectrum beta-lactamases among clinical isolates of Klebsiella pneumoniae in central China. Int J Antimicrob Agents 2003; 22: 521-525.
14. Munday C. J., Xiong J., Li C., Shen D., Hawkey P. M. Dissemination of CTX-M type beta-lactamases in Enterobacteriaceae isolates in the People's Republic of China. Ibid; 2004; 23: 175-180.
15. Paterson D. L., Hujer K. M., Hujer A. M. et al. Extended-spectrum β- lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47: 3554-3560.
16. Neuwirth C., Siebor E., Pruneaux M. et al. First isolation of CTX-M15-producing Escherichia coli from two French patients. J Antimicrob Chemother 2003; 51: 471-473.
17. Pagani L., Dell'Amico E., Migliavacca R. et al. Multiple CTX-M-type extended-spectrum β-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northern Italy. J Clin Microbiol 2003; 41: 4264-4269.
18. Mushtaq S., Woodford N., Potz N., Livermore D. M. Detection of CTX-M-15 extended-spectrum β-lactamase in the United Kingdom. J Antimicrob Chemother 2003; 52: 528-529.
19. Paterson D. L., Ko W. C., Von Gottberg A. et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
20. Medeiros A. A., Crellin J. Comparative susceptibility of clinical isolates producing extended spectrum β-lactamases to ceftibuten: effect of large inocula. Pediatr Infect Dis J 1997, 16: S49-S55.
21. Bedenic B., Beader N., Zagar Z. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases. Clin Microbiol Infect 2001, 7: 626-635.
22. Rice L. B., Carias L. L., Shlaes D. M. Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model. Antimicrob Agents Chemother 1993; 37: 610-612.
23. Pefanis A., Thauvin-Eliopoulos C., Eliopoulos G. M., Moellering R. C. Efficacy of ceftriaxone plus tazobactam in a rat model of intraabdominal abscess due to Bacteroides fragilis. J Antimicrob Chemother 1993, 32: 307-312.
24. Wong-Beringer A., Hindler J., Loeloff M. et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34: 135-146.
25. Ho P. L., Tsang D. N., Que T. L., Ho M., Yuen K. Y. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among Escherichia coli and Klebsiella species in Hong Kong. APMIS 2000; 108: 237-240.
26. Gibb A. P., Crichton M. Cefpodoxime screening of Escherichia coli and Klebsiella spp. by Vitek for detection of organisms producing extended-spectrum β-lactamases. Diagn Microbiol Infect Dis 2000; 38: 255-257.
27. Jacoby G. A., Han P. Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 1996; 34: 908-911.
28. Steward C. D., Wallace D., Hubert S. K. et al. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis 2000; 38: 59-67.
29. Xu Y., Chen M., Biedenbach D. J. et al. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum β-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chin Antimicrob Resist Study Group. Diagn Microbiol Infect Dis 1999; 35: 135-142.
30. Gales A. C., Jones R. N., Gordon K. A. et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Chemother 2000; 45: 295-303.
31. Pfaller M. A., Jones R. N., Doern G. V., Salazar J. C. Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia: comparison of data from 1997 and 1998 using the E-test method. The Colombian Antimicrob Resist Study Group. Diagn Microbiol Infect Dis 1999; 35: 235-241.
32. Pfaller M. A., Korten V., Jones R. N., Doern G. V. Multicenter evaluation of the antimicrobial activity for seven broad-spectrum β-lactams in Turkey using the E-test method. Turkish Antimicrob Resist Study Group. Ibid 1999; 35: 65-73.
33. Nagano N., Shibata N., Saitou Y., Nagano Y., Arakawa Y. Nosocomial outbreak of infections by Proteus mirabilis that produces extended-spectrum CTX-M-2 type β-lactamase. J Clin Microbiol 2003; 41: 5530-5536.
34. Franceschini N., Segatore B., Perilli M. et al. Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several β-lactamase-producing Gram-negative strains. J Antimicrob Chemother 2002;49: 2: 395-398.
35. Nordmann P., Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-331.
36. Raimondi A., Traverse A., Nikaido H. Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins. Antimicrob Agents Chemother 1991; 35: 1174-1180.
37. Melano R., Corso A., Petroni A. et al. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina. J Antimicrob Chemother 2003; 52: 36.